The ASRA releases its fifth iteration of evidence-based guidelines on regional anesthesia in patients on antithrombotic or ...

Included patients were receiving anticoagulation therapy at the time of preeducation knowledge assessment administration (July-August 2003). Patients unable to communicate through written or oral ...

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

AstraZeneca's anticoagulant reversal agent Andexxa was ... so keeping the only approved therapy on the market makes sense, even if the FDA asks for additional data.

Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It increases the risk of stroke because blood clots can form in the heart and ...

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new ...

Oral anticoagulant or antiplatelet medication use had no substantial effect on the accuracy of multitarget stool DNA testing for colorectal cancer, according to a study published in Gastro Hep ...

Together, these results suggest a need for further interrogation of the role of thrombosis in GCA, and to elucidate whether anticoagulant therapy alongside glucocorticoids might be beneficial in ...

Tecarfarin is designed to be a superior and safer chronic oral anticoagulant therapy compared to warfarin for patients with implanted cardiac devices or rare cardiovascular conditions. Cadrenal ...

By Dr. Chinta Sidharthan Promising results show that abelacimab could revolutionize anticoagulation therapy by slashing bleeding risks without compromising stroke protection for patients with atrial ...